FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

Core Viewpoint - FOXO Technologies Inc. is currently facing noncompliance issues with the NYSE due to a reported stockholders' deficit of $14.9 million as of March 31, 2024, and losses from continuing operations over the last three fiscal years [6]. Compliance and Regulatory Issues - The company has received an official notice from NYSE Regulation indicating noncompliance with Section 1003(a)(ii) of the Company Guide [6]. - FOXO must adhere to compliance deadlines set by NYSE, including a plan acceptance letter dated August 29, 2023, and must confirm receipt of the NYSE American Notice by July 16, 2024 [1][7]. Management's Response - Mark White, Interim CEO of FOXO, acknowledged the delinquency was due to short-term capital allocation strategies and expressed the company's intention to regain compliance with NYSE standards [3]. - The company is in discussions with NYSE regarding its compliance plan, which includes planned acquisitions expected to generate significant cash flow [3]. Company Overview - FOXO Technologies Inc. is a biotechnology firm focused on enhancing human health and longevity through innovative technology and product solutions, particularly in the life insurance sector [10]. - The company utilizes AI to analyze DNA methylation for identifying molecular biomarkers related to health and aging [10].